NCT03866109CompletedPhase 1/2
A clinical gene therapy study with hematopoietic stem cells for the treatment of patients suffering from a malignant neoplasm of the central nervous system
Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Sept 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- First submitted
- 26 Jan 2024
- Start date
- 13 Mar 2019
- Lead sponsor
- Genenta Science S.p.A.
- Diseases
- Glioblastoma
- NCT number
- NCT03866109
- EU CT number
- 2023-510299-29-00
- EudraCT number
- 2018-001404-11
What you commit to
- Study type: Interventional · Phase 1/2
- Participants enrolled: 27
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Ospedale San Raffaele S.r.l. Coordinator of this site? Confirm its status | Milan | Italy | Completed |
| IRCCS Foundation Istituto Neurologico Carlo Besta Coordinator of this site? Confirm its status | Milan | Italy | Completed |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS Coordinator of this site? Confirm its status | Rome | Italy | Completed |
Related publications
- Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial.Nat Med · 2026 · PMID 42225991
This page is information, not medical advice. Discuss any trial with your doctor.